UPDATED Jun 19, 2024
Companies in consumer staple industries including durables, food, beverage, tobacco, and household and personal products.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
LLY * | US$16,349.92 | 0.3% | 110.3% | US$802.7b | US$15,688.29 | PE130.8x | E27.3% | 0.6% | ||
NOVOB N | kr.2,661.00 | -1.7% | 92.0% | kr.4.4t | kr.2,526.00 | PE49.1x | E13.3% | 1.0% | ||
NVO N | kr.2,605.00 | -2.6% | 90.1% | kr.4.4t | kr.2,472.85 | PE49.1x | E13.3% | 1.0% | ||
JNJ * | US$2,676.00 | -1.8% | -5.5% | US$350.5b | US$3,154.92 | PE20.5x | S4.4% | 3.4% | ||
MRK * | US$2,343.00 | -4.8% | 23.1% | US$324.2b | US$2,611.95 | PE140.6x | E23.7% | 2.4% | ||
ABBV * | US$3,157.70 | 1.5% | 35.2% | US$302.6b | US$3,376.52 | PE50.8x | E23.0% | 3.6% | ||
AZN1 N | UK£2,619.82 | 0% | n/a | UK£192.5b | UK£2,883.27 | PE38.7x | E14.7% | 2.0% | ||
AZN N | UK£1,440.00 | -2.0% | 14.0% | UK£191.3b | UK£1,594.57 | PE38.4x | E14.7% | 2.0% | ||
ROG N | CHF5,258.18 | 1.4% | -2.3% | CHF202.0b | CHF5,897.74 | PE17.2x | E8.5% | 3.9% | ||
TMO * | US$10,439.01 | -1.5% | 15.8% | US$217.3b | US$11,544.99 | PE36x | E10.6% | 0.3% | ||
NVS N | CHF1,851.08 | 0% | n/a | CHF191.6b | CHF1,922.63 | PE23.8x | E10.2% | 3.4% | ||
NOVN N | CHF1,719.29 | 0% | n/a | CHF180.4b | CHF1,885.96 | PE26.2x | E10.1% | 3.5% | ||
DHR * | US$4,750.00 | -4.8% | 16.6% | US$190.7b | US$5,041.48 | PE46.9x | E13.8% | 0.4% | ||
AMGN * | US$5,185.00 | 0% | 34.6% | US$164.1b | US$5,362.09 | PE43.6x | E18.2% | 2.9% | ||
PFE * | US$500.00 | -3.1% | -24.9% | US$155.3b | US$582.19 | PS2.8x | E30.6% | 6.1% | ||
SAN1 N | €1,629.20 | 0% | -11.4% | €115.5b | €1,878.23 | PE12.7x | E5.7% | 3.9% | ||
VRTX * | US$8,641.93 | -3.1% | 45.5% | US$120.6b | US$8,570.54 | PE30x | E10.4% | n/a | ||
SNY N | €874.00 | -4.6% | -4.6% | €108.5b | €1,068.34 | PE24.4x | E17.0% | 4.2% | ||
REGN * | US$19,357.85 | 8.1% | 50.1% | US$112.1b | US$19,588.10 | PE29.1x | E12.5% | n/a | ||
CSL N | AU$3,635.42 | 0% | n/a | AU$145.0b | AU$4,103.81 | PE45.3x | E17.9% | 1.1% | ||
GSK1 N | UK£357.35 | 0% | n/a | UK£72.4b | UK£409.15 | PE16.1x | E12.2% | 3.3% | ||
GSK N | UK£756.56 | -1.2% | n/a | UK£65.9b | UK£955.78 | PE14.7x | E12.3% | 3.6% | ||
BMY * | US$753.17 | -4.5% | -33.6% | US$82.7b | US$981.73 | PS1.8x | E44.7% | 5.9% | ||
GILD * | US$1,166.00 | -0.8% | -12.5% | US$78.7b | US$1,526.93 | PE162.2x | E36.2% | 4.9% |